AU2019226009B2 - B7-H4 antibody dosing regimens - Google Patents

B7-H4 antibody dosing regimens

Info

Publication number
AU2019226009B2
AU2019226009B2 AU2019226009A AU2019226009A AU2019226009B2 AU 2019226009 B2 AU2019226009 B2 AU 2019226009B2 AU 2019226009 A AU2019226009 A AU 2019226009A AU 2019226009 A AU2019226009 A AU 2019226009A AU 2019226009 B2 AU2019226009 B2 AU 2019226009B2
Authority
AU
Australia
Prior art keywords
antibody
antigen
binding fragment
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019226009A
Other languages
English (en)
Other versions
AU2019226009A1 (en
Inventor
Helen L. COLLINS
Sandeep P. INAMDAR
Hong Xiang
Xiang Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Five Prime Therapeutics Inc
Original Assignee
Five Prime Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics Inc filed Critical Five Prime Therapeutics Inc
Publication of AU2019226009A1 publication Critical patent/AU2019226009A1/en
Application granted granted Critical
Publication of AU2019226009B2 publication Critical patent/AU2019226009B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2019226009A 2018-02-21 2019-02-21 B7-H4 antibody dosing regimens Active AU2019226009B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862633527P 2018-02-21 2018-02-21
US62/633,527 2018-02-21
US201962802100P 2019-02-06 2019-02-06
US62/802,100 2019-02-06
PCT/US2019/018963 WO2019165075A1 (en) 2018-02-21 2019-02-21 B7-h4 antibody dosing regimens

Publications (2)

Publication Number Publication Date
AU2019226009A1 AU2019226009A1 (en) 2020-09-03
AU2019226009B2 true AU2019226009B2 (en) 2025-11-20

Family

ID=65686103

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019226009A Active AU2019226009B2 (en) 2018-02-21 2019-02-21 B7-H4 antibody dosing regimens

Country Status (12)

Country Link
US (3) US20210070862A1 (cg-RX-API-DMAC7.html)
EP (1) EP3755719A1 (cg-RX-API-DMAC7.html)
JP (2) JP7258038B6 (cg-RX-API-DMAC7.html)
KR (1) KR102863169B1 (cg-RX-API-DMAC7.html)
CN (1) CN111868089B (cg-RX-API-DMAC7.html)
AU (1) AU2019226009B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020016990A2 (cg-RX-API-DMAC7.html)
IL (1) IL276623A (cg-RX-API-DMAC7.html)
MA (1) MA51902A (cg-RX-API-DMAC7.html)
MX (1) MX2020008730A (cg-RX-API-DMAC7.html)
SG (1) SG11202007820QA (cg-RX-API-DMAC7.html)
WO (1) WO2019165075A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202000387YA (en) 2017-08-25 2020-03-30 Five Prime Therapeutics Inc B7-h4 antibodies and methods of use thereof
WO2019165077A1 (en) * 2018-02-21 2019-08-29 Five Prime Therapeutics, Inc. B7-h4 antibody formulations
KR20200144094A (ko) 2018-03-02 2020-12-28 파이브 프라임 테라퓨틱스, 인크. B7-h4 항체 및 이의 사용 방법
AU2019361923B2 (en) * 2018-10-15 2026-07-09 Five Prime Therapeutics, Inc. Combination therapy for cancer
WO2022147532A1 (en) 2021-01-04 2022-07-07 Mersana Therapeutics, Inc. B7h4-targeted antibody-drug conjugates and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014100483A1 (en) * 2012-12-19 2014-06-26 Amplimmune, Inc. Anti-human b7-h4 antibodies and their uses

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
US7029872B2 (en) 2000-06-28 2006-04-18 Glycofi, Inc Methods for producing modified glycoproteins
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
JPWO2002030954A1 (ja) 2000-10-06 2004-02-19 協和醗酵工業株式会社 抗体を精製する方法
CN103333860B (zh) 2000-10-06 2015-07-08 协和发酵麒麟株式会社 产生抗体组合物的细胞
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
CA2923247A1 (en) 2002-03-19 2003-09-25 Stichting Dienst Landbouwkundig Onderzoek Optimizing glycan processing in plants
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
KR101498588B1 (ko) 2003-01-22 2015-03-05 로슈 글리카트 아게 융합 구성체와 Fc 수용체 결합 친화도 및 이펙터 기능이 증가된 항체를 생성하기 위한 이의 용도
EP1888649A2 (en) 2005-05-09 2008-02-20 GlycArt Biotechnology AG Antigen binding molecules having modified fc regions and altered binding to fc receptors
MX2008009220A (es) 2006-01-17 2008-10-10 Biolex Therapeutics Inc Composiciones y metodos para la humanizacion y optimizacion de n-glicanos en plantas.
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
US9676854B2 (en) * 2011-08-15 2017-06-13 Medimmune, Llc Anti-B7-H4 antibodies and their uses
MX374785B (es) 2013-08-01 2025-03-06 Five Prime Therapeutics Inc Anticuerpos anti-fgfr2iiib afucosilados.
CN107299085B (zh) * 2017-05-26 2020-09-29 广东医科大学 分泌抗人b7-h4胞外单克隆抗体杂交瘤细胞株和抗人b7-h4单克隆抗体及其应用
SG11202000387YA (en) 2017-08-25 2020-03-30 Five Prime Therapeutics Inc B7-h4 antibodies and methods of use thereof
WO2019165077A1 (en) 2018-02-21 2019-08-29 Five Prime Therapeutics, Inc. B7-h4 antibody formulations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014100483A1 (en) * 2012-12-19 2014-06-26 Amplimmune, Inc. Anti-human b7-h4 antibodies and their uses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HYUNGJUN JEON ET AL: "Structure and Cancer Immunotherapy of the B7 Family Member B7x", CELL REPORTS, vol. 9, no. 3, 1 November 2014 (2014-11-01), US, pages 1089 - 1098, XP055510316, ISSN: 2211-1247, DOI: 10.1016/j.celrep.2014.09.053 *

Also Published As

Publication number Publication date
US20240317864A1 (en) 2024-09-26
JP7258038B2 (ja) 2023-04-14
BR112020016990A2 (pt) 2021-02-23
EP3755719A1 (en) 2020-12-30
CN111868089A (zh) 2020-10-30
IL276623A (en) 2020-09-30
WO2019165075A1 (en) 2019-08-29
MX2020008730A (es) 2020-12-07
MA51902A (fr) 2021-05-26
KR102863169B1 (ko) 2025-09-22
JP2023089063A (ja) 2023-06-27
CN111868089B (zh) 2025-08-22
US20210070862A1 (en) 2021-03-11
JP7258038B6 (ja) 2023-04-25
SG11202007820QA (en) 2020-09-29
JP2021513997A (ja) 2021-06-03
AU2019226009A1 (en) 2020-09-03
US20230287123A1 (en) 2023-09-14
CA3091161A1 (en) 2019-08-29
KR20200123169A (ko) 2020-10-28

Similar Documents

Publication Publication Date Title
US12435145B2 (en) B7-H4 antibody formulations
EP3356532B1 (en) Agonistic antibodies specifically binding human cd40 and methods of use
US20240317864A1 (en) B7-h4 antibody dosing regimens
TWI835885B (zh) 用於癌症之組合療法
AU2018366650A1 (en) Single-domain antibodies and variants thereof against PD-L1
KR20180081606A (ko) 암 치료에서의 단독의, 또는 면역 자극제와 병용한, fgfr2 억제제
CA3091161C (en) B7-h4 antibody dosing regimens
TW202400656A (zh) 使用ctla-4及pd-1雙特異性抗體之治療方法
EA048025B1 (ru) Комбинированная терапия онкологического заболевания
HK40036127B (zh) B7-h4抗体给药方案
HK40036127A (en) B7-h4 antibody dosing regimens

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)